Knott David M Jr Acquires Shares of 32,927 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Knott David M Jr purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 32,927 shares of the specialty pharmaceutical company's stock, valued at approximately $943,000. Collegium Pharmaceutical comprises approximately 0.3% of Knott David M Jr's portfolio, making the stock its 29th biggest holding. Knott David M Jr owned approximately 0.10% of Collegium Pharmaceutical as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of COLL. Nisa Investment Advisors LLC lifted its position in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after purchasing an additional 316 shares in the last quarter. AlphaQuest LLC increased its holdings in Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company's stock worth $366,000 after acquiring an additional 374 shares in the last quarter. Gallacher Capital Management LLC raised its stake in Collegium Pharmaceutical by 3.3% during the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company's stock worth $417,000 after acquiring an additional 470 shares during the period. TD Private Client Wealth LLC raised its stake in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after acquiring an additional 483 shares during the period. Finally, Caprock Group LLC lifted its holdings in Collegium Pharmaceutical by 6.7% during the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company's stock valued at $249,000 after purchasing an additional 543 shares in the last quarter.

Collegium Pharmaceutical Price Performance

Shares of COLL traded down $0.88 during midday trading on Friday, hitting $28.14. 384,608 shares of the company traded hands, compared to its average volume of 437,860. The stock has a market cap of $904.19 million, a price-to-earnings ratio of 12.13 and a beta of 0.76. The firm has a 50 day moving average of $30.02 and a 200-day moving average of $32.19. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. On average, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler lowered their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $43.60.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 10,445 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares in the company, valued at $4,959,032.46. The trade was a 5.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is owned by corporate insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.